Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
OBJECTIVE
To assess the potential value of pre-operative CEA, CA 125 and CA 19-9 in identifying Pseudomyxoma peritonei (PMP) patients at risk of recurrence following complete cytoreductive surgery and intraperitoneal chemotherapy.


METHODS
Between March 1996 and October 2001, 35 patients, with documented pre-operative tumour marker measurements, underwent complete cytoreduction. Outcome in the 32 survivors was recorded.


RESULTS
Median age was 53 years (range: 32-74). There were 17[53%] females. In 9/32[28%] all tumour markers were normal. The most common abnormality was elevated CEA level in 14/32[44%]. Median follow up was 23 months (range: 11-74). Recurrence was detected in 8/32[25%]. The 2-year recurrence free interval was 53% in those with elevated CEA compared with 94% with normal CEA. The 2-year disease free intervals were 100% in 9 patients with normal preop markers compared with 66% for the group with at least one abnormal marker.


CONCLUSIONS
PMP patients with elevated CEA, or more than one abnormal serum tumour maker, are at risk of developing recurrent disease.
Alexander-Sefre
F
F
The North Hampshire Hospital, Basingstoke, UK.
Chandrakumaran
K
K
Banerjee
S
S
Sexton
R
R
Thomas
J M
JM
Moran
B
B
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood*; D013505:Digestive System Surgical Procedures / Q000379:methods; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D010534:Peritoneal Neoplasms / Q000097:blood* / Q000628:therapy; D011237:Predictive Value of Tests; D011300:Preoperative Care; D011553:Pseudomyxoma Peritonei / Q000097:blood* / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D016685:Mitomycin